Data / Drug companies / Vancomycin hydrochloride
Vancomycin hydrochloride: 39 companies and 153 products in the FDA NDC directory
Vancomycin hydrochloride is listed in the FDA National Drug Code Directory by 39 companies, with 153 products in commercial distribution. 115 of the products (75.2%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are injection, powder, lyophilized, for solution; capsule; injection, powder, for solution, and the newest product started marketing on October 12, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 39
- Products
- 153
- Generic (ANDA) products
- 115 (75.2%)
- Application numbers
- 42
- Routes
- Intravenous, Oral, Intravitreal
- Brand names
- Firvanq, Vancomycin, Vancocin
- openFDA record search
- api.fda.gov
Companies that list vancomycin hydrochloride
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Fresenius Kabi USA, LLC | 15 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 3, 2021 |
| Hikma Pharmaceuticals USA Inc. | 14 | injection, powder, for solution; injection, powder, lyophilized, for solution | Generic drugs (ANDA) | August 13, 2025 |
| Baxter Healthcare Corporation | 8 | injection, solution | New drug applications (NDA) | November 14, 1958 |
| Hospira, Inc. | 8 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | November 2, 2021 |
| Gland Pharma Limited | 7 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | March 21, 2025 |
| Glenmark Pharmaceuticals Inc., USA | 7 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | October 12, 2026 |
| Mylan Institutional LLC | 7 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | December 6, 2018 |
| Sagent Pharmaceuticals | 7 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | June 1, 2025 |
| Eugia US LLC | 6 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | August 4, 2023 |
| Ani Pharmaceuticals, Inc. | 5 | capsule; powder, for solution | Authorized generics (NDA) | September 9, 2019 |
| Meitheal Pharmaceuticals Inc. | 5 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | September 15, 2022 |
| Azurity Pharmaceuticals, Inc. | 4 | kit | New drug applications (NDA) | January 26, 2018 |
| Heritage Pharmaceuticals Inc. D/B/A Avet Pharmaceuticals Inc. | 4 | capsule | Generic drugs (ANDA) | August 10, 2026 |
| Slate Run Pharmaceuticals, LLC | 4 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | February 6, 2021 |
| Wilshire Pharmaceuticals, Inc. | 4 | kit | Authorized generics (NDA) | March 31, 2023 |
| Avenacy, LLC | 3 | injection, powder, for solution | New drug applications (NDA) | August 15, 2026 |
| Bryant Ranch Prepack | 3 | capsule; powder, for solution | Generic drugs (ANDA) | January 15, 2024 |
| Bryant Ranch Prepack | 3 | powder, for solution | Generic drugs (ANDA) | September 9, 2019 |
| Civica, Inc. | 3 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | November 10, 2025 |
| Steriscience Specialties Private Limited | 3 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | December 15, 2025 |
| Ascend Laboratories, LLC | 2 | kit | Generic drugs (ANDA) | August 1, 2023 |
| Aurobindo Pharma Limited | 2 | kit | Generic drugs (ANDA) | August 7, 2026 |
| BluePoint Laboratories | 2 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | August 23, 2019 |
| Bryant Ranch Prepack | 2 | powder, for solution | Generic drugs (ANDA) | September 9, 2019 |
| Camber Pharmaceuticals, Inc. | 2 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | July 6, 2022 |
| Cameron Pharmaceuticals | 2 | capsule | Generic drugs (ANDA) | January 15, 2024 |
| Medimetriks Pharmaceuticals, Inc. | 2 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | June 30, 2008 |
| Mylan Institutional LLC | 2 | injection, powder, lyophilized, for solution | New drug applications (NDA) | July 23, 2024 |
| Pai Holdings, LLC DBA Pai Pharma | 2 | capsule | Generic drugs (ANDA) | May 1, 2026 |
| Plano Pharmaceuticals Inc. | 2 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | August 10, 2012 |
| Redpharm Drug | 2 | capsule | Generic drugs (ANDA) | January 1, 2026 |
| Strides Pharma Science Limited | 2 | capsule | Generic drugs (ANDA) | January 1, 2026 |
| XGen Pharmaceuticals DJB, Inc. | 2 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | December 15, 2025 |
| Xellia Pharmaceuticals USA LLC | 2 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | February 23, 2016 |
| Advanced Rx of Tennessee, LLC | 1 | capsule | Authorized generics (NDA) | April 18, 2025 |
| Amneal Pharmaceuticals NY LLC | 1 | solution | Generic drugs (ANDA) | June 26, 2023 |
| Henry Schein, Inc. | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | January 11, 2022 |
| Samson Medical Technologies LLC | 1 | injection, powder, lyophilized, for solution | Generic drugs (ANDA) | June 1, 2016 |
| Zhejiang Novus Pharma Co., Ltd. | 1 | injection, powder, for solution | New drug applications (NDA) | August 23, 2024 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, powder, lyophilized, for solution | 93 | 60.8% |
| Capsule | 19 | 12.4% |
| Injection, powder, for solution | 13 | 8.5% |
| Kit | 12 | 7.8% |
| Injection, solution | 8 | 5.2% |
| Powder, for solution | 7 | 4.6% |
| Solution | 1 | 0.7% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 115 | 75.2% |
| New drug applications (NDA) | 30 | 19.6% |
| Authorized generics (NDA) | 8 | 5.2% |
Pharmacologic classes
| Class | Products |
|---|---|
| Glycopeptide Antibacterial | 141 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.